Innate Pharma has secured $30.0M in new funding, a capital injection that arrives as the Marseille-based biotech continues to push its pipeline of therapeutic antibodies designed to harness the immune system against cancer.
The clinical-stage company, listed on both Euronext Paris and Nasdaq, has built its reputation on natural killer cell biology and a broad roster of potentially first-in-class candidates targeting cancers with high unmet need. Its partnerships with heavyweights like Bristol-Myers Squibb, Sanofi, and AstraZeneca underscore the depth of its platform, though specifics on the round’s backers or intended use of the proceeds were not disclosed.
